Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07116850) titled 'Adjunctive iTBS for First-Episode Schizophrenia' on Aug. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: The First Hospital of Hebei Medical University
Condition:
Schizophrenia Disorder
Intervention:
Device: Intermittent Theta-Burst Stimulation (iTBS)
Drug: Risperidone
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: January 1, 2024
Target Sample Size: 100
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/ct2/...